Fresenius Medical Care AG (NYSE:FMS) shares are rebounding from earlier losses and were back to within 50 cents of even for today’s session at $68.14 each, after the German medical device manufacturer announced plans to acquire the Crit-Line system from privately held Hema Metrics. Terms of the deal were not immediately available.
The Crit-Line III is a non-invasive monitor designed to measure and manage the ratio of fluids and red blood cells in dialysis patients. The graphic display lists metrics such as blood volume changes over time as well as alphanumeric output of hematocrit and oxygen levels. The Crit-Line and associated products are 510(k)-cleared by the FDA and also carry the CE mark for European sales.
Fresenius, which last month moved to challenge NxStage Medical in the home dialysis market, said Crit-Line will be a good fit with its existing line of hemodialysis machines and that the Hema Metrics sales organization will augment its position in the North American market.